Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

The study created a model to help design new inhibitors for steroidal 5α-reductase enzymes.

Finasteride lowers DHT levels and raises testosterone in a dose-dependent way.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Exercise improves insulin sensitivity and hormone regulation in PCOS rats.

New progesterone-based compounds can block male hormones.

Using finasteride or dutasteride does not increase the risk of male breast cancer.

Compound 7b is a promising candidate for treating benign prostatic hyperplasia and prostate cancer.

5ARI treatment improves PSA test accuracy for prostate cancer diagnosis.

New compounds were made and tested, with compound 6 showing potential for treating prostate-related diseases.

New compounds were made that block an enzyme linked to breast cancer better than existing treatments.

Finasteride may treat baldness but less effective for those with 5α-reductase deficiency.

Steroid Sulfatase inhibitors show promise in treating hormone-dependent disorders like cancers, hair loss, and acne, with 667COUMATE being a potential candidate for breast cancer treatment trials.

Certain progesterone derivatives can inhibit enzymes and reduce androgenic activity, potentially affecting prostate growth.

GI198745 is more potent and longer-lasting than finasteride, potentially better for treating hair loss.

5α-reductase inhibitors effectively treat enlarged prostate and hair loss but require careful use due to possible side effects.

Androgens may influence bladder cancer progression by affecting cellular behavior.

5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.

The androgen receptor's shape-changing ability helps it function but can lead to cancer treatment resistance.

The enzyme steroid sulfatase is linked to breast cancer and other conditions, and inhibitors are being developed for treatment.

Certain Dibenzo derivatives may help treat prostate cancer.

PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.

The study created a new method to test drugs that affect hormone processing in skin.

SARM-induced changes in the androgen receptor are specific to each ligand and affect stability and protein interactions.

Certain gene variations in AKT2 are more common in women with PCOS and are linked to higher levels of specific hormones and symptoms.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

The new compound may be a safer alternative to finasteride for prostate protection.